MYGN Nasdaq In Vitro & In Vivo Diagnostic Substances Financials FY2015βFY2025
Myriad Genetics Inc had $825M of revenue in fiscal 2025, down 1.6% on the year before. Over five years, revenue changed +5.2% a year on average.
Last close Β· Oct 23, 2026
$5.82
1.0%Hi! I read Myriad Genetics Incβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β1.6%
No. Sales fell 1.6% last year.
Does it make a profit?
β44.4%
No. It lost money last year.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Myriad Genetics Inc did it, and the next one. Share prices often move a lot on those days.
Next results
November 4, 2026
Wednesday Β· in 9 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Jul 30, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 5, 2026 | Q1 '26 | After the market closes | 8-K β |
| Jan 12, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Nov 3, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 5, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 6, 2025 | Q1 '25 | After the market closes | 8-K β |
| Jan 15, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Oct 9, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Myriad Genetics Inc had $825M of revenue in fiscal 2025, down 1.6% on the year before. Over five years, revenue changed +5.2% a year on average. Its operating margin was β47.0%, down 32.2Β pts: of every 100 in sales, about β47 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Myriad Genetics Inc lost $366M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Myriad Genetics Inc has $29.7M more cash than debt.
Cash, debt and the ratios that show how comfortably Myriad Genetics Inc can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $339M | $115M | $141M | $102M | $150M |
| Debt incl. finance leases | $0.0M | $0.0M | $38.5M | $39.6M | $120M |
| Debt / equity | 0.0x | 0.0x | 0.0x | 0.1x | 0.3x |
| Interest coverage | β28.9x | β43.9x | β88.8x | β44.1x | β36.9x |
| Current ratio | 2.4x | 2.0x | 2.0x | 1.8x | 2.5x |
| Quick ratio | 2.3x | 1.9x | 1.9x | 1.6x | 2.3x |
| Total assets | $1.3B | $1.2B | $1.1B | $1.0B | $707M |
| Total liabilities | $353M | $313M | $363M | $327M | $339M |
| Shareholders' equity | $968M | $886M | $783M | $701M | $368M |
| Net debt (β = net cash) | β$339M | β$115M | β$102M | β$62.8M | β$29.7M |
KIRA Β· Its return on capital was β90.4%: every 100 invested in the business earned about β90 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Myriad Genetics Inc passes 5 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY15 | FY16 | FY17 | FY18 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 8 | 5 / 8 | 3 / 8 | β / 3 | 5 / 8 | 2 / 8 | 3 / 9 | 4 / 9 | 5 / 9 |
| Accruals ratio | β5.6% | β8.5% | 1.5% | β5.8% | β18.3% | β3.3% | β0.5% | β13.0% | β10.9% | β42.4% |
| Altman Z'' | 8.57 | 2.32 | 6.95 | 3.47 | 1.23 | 2.68 | 1.94 | β0.13 | β0.10 | β5.88 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY15 | FY16 | FY17 | FY18 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $754M | $771M | $744M | $851M | $639M | $691M | $678M | $753M | $838M | $825M |
| Gross profit | $621M | $626M | β | β | β | β | $476M | $517M | $585M | $577M |
| Research and development | $70.6M | $74.4M | $70.8M | $85.9M | $77.2M | $81.9M | $85.4M | $88.7M | $113M | $107M |
| Operating income | $153M | $44.0M | $122M | $7.6M | β$232M | β$191M | β$141M | β$257M | β$124M | β$387M |
| Interest expense | $0.3M | $6.0M | $3.2M | $12.0M | $10.8M | $6.6M | $3.2M | $2.9M | $2.8M | $10.5M |
| Pretax income | $156M | $36.2M | $120M | $0.0M | β$223M | β$57.1M | β$141M | β$262M | β$124M | β$395M |
| Income tax | $38.8M | $19.0M | β$13.0M | β$4.4M | β$23.7M | β$29.9M | β$28.6M | $1.1M | $3.8M | β$29.2M |
| Net income | $117M | $17.4M | $133M | $4.6M | β$200M | β$27.2M | β$112M | β$263M | β$127M | β$366M |
| Diluted EPS | $1.60 | $0.25 | $1.85 | $0.06 | β$2.69 | β$0.35 | β$1.39 | β$3.18 | β$1.41 | β$3.95 |
| Diluted shares | 0.07B | 0.07B | 0.07B | 0.08B | 0.07B | 0.08B | 0.08B | 0.08B | 0.09B | 0.09B |
| Cash flow | ||||||||||
| Cash from operations | $166M | $106M | $116M | $83.7M | $60.7M | $18.6M | β$106M | β$111M | β$8.7M | $1.8M |
| Capital expenditure | $5.0M | $6.1M | $8.4M | $8.6M | $10.2M | $18.0M | $45.3M | β | β | β |
| Free cash flow | $161M | $100M | $108M | $75.1M | $50.5M | $0.6M | β$152M | β | β | β |
| Depreciation and amortization | $26.8M | $48.3M | $54.4M | $73.0M | $72.0M | $62.8M | $52.7M | $61.9M | $61.2M | $53.7M |
| Stock-based compensation | $31.6M | $29.9M | $27.1M | $33.5M | $25.2M | $36.3M | $38.1M | $40.7M | $49.8M | $35.2M |
| Acquisitions | $37.0M | $216M | $0.0M | $279M | $0.0M | $0.0M | $57.2M | $0.0M | $0.0M | β |
| Share buybacks | $163M | $31.6M | $0.0M | $50.0M | $0.0M | $0.0M | β | β | β | β |
| Dividends and buybacks | $163M | $31.6M | $0.0M | $50.0M | $0.0M | $0.0M | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $159M | $151M | $181M | $137M | $151M | $339M | $115M | $141M | $102M | $150M |
| Total debt | β | $99.1M | $9.3M | $234M | $225M | $0.0M | $0.0M | $38.5M | $39.6M | $120M |
| Current assets | $315M | $302M | $328M | $349M | $389M | $485M | $275M | $314M | $298M | $333M |
| Current liabilities | $72.3M | $218M | $102M | $118M | $146M | $204M | $137M | $156M | $164M | $134M |
| Inventory | $38.3M | $42.2M | $34.3M | $31.4M | $27.1M | $15.3M | $20.1M | $22.0M | $27.5M | $30.6M |
| Property and equipment, net | $58.3M | $51.1M | $43.2M | $57.3M | $40.7M | $43.5M | $83.4M | $119M | $117M | $114M |
| Goodwill | $195M | $316M | $319M | $417M | $329M | $239M | $287M | $287M | $286M | $51.6M |
| Intangible assets | $228M | $492M | $455M | $685M | $577M | $404M | $380M | $350M | $262M | $153M |
| Total assets | $881M | $1.2B | $1.2B | $1.6B | $1.4B | $1.3B | $1.2B | $1.1B | $1.0B | $707M |
| Total liabilities | $132M | $441M | $209M | $474M | $538M | $353M | $313M | $363M | $327M | $339M |
| Shareholders' equity | $740M | $768M | $966M | $1.1B | $881M | $968M | $886M | $783M | $701M | $368M |
| Margins | ||||||||||
| Gross margin | 82.4% | 81.2% | β | β | β | β | 70.2% | 68.6% | 69.9% | 69.9% |
| Operating margin | 20.4% | 5.7% | 16.4% | 0.9% | β36.3% | β27.6% | β20.7% | β34.2% | β14.7% | β47.0% |
| EBITDA margin | 23.9% | 12.0% | 23.7% | 9.5% | β25.0% | β18.5% | β13.0% | β26.0% | β7.4% | β40.4% |
| Net margin | 15.5% | 2.3% | 17.9% | 0.5% | β31.2% | β3.9% | β16.5% | β35.0% | β15.2% | β44.4% |
| FCF margin | 21.4% | 13.0% | 14.5% | 8.8% | 7.9% | 0.1% | β22.3% | β | β | β |
| Returns | ||||||||||
| Return on capital | β | 4.0% | 15.3% | 0.5% | β19.2% | β23.9% | β14.4% | β29.9% | β15.3% | β90.4% |
| Return on capital employed | 19.0% | 4.4% | 11.4% | 0.5% | β18.2% | β17.1% | β13.2% | β26.0% | β14.3% | β67.6% |
| Return on equity | 15.8% | 2.3% | 15.4% | 0.4% | β22.6% | β2.9% | β12.1% | β31.6% | β17.2% | β68.5% |
| Return on assets | 13.3% | 1.7% | 11.2% | 0.3% | β14.1% | β2.0% | β8.9% | β22.5% | β11.7% | β42.2% |
| Return on tangible equity | 37.0% | β | 69.3% | β | β | β8.4% | β51.1% | β180.0% | β83.5% | β224.5% |
| Growth | ||||||||||
| Revenue growth | β | 2.3% | β3.6% | 14.4% | β | 8.1% | β1.8% | 11.0% | 11.2% | β1.6% |
| Net income growth | β | β85.2% | 666.1% | β96.5% | β | β | β | β | β | β |
| EPS growth | β | β84.4% | 640.0% | β96.8% | β | β | β | β | β | β |
| FCF growth | β | β37.9% | 7.4% | β30.1% | β | β98.8% | β25,366.7% | β | β | β |
| Share count change | β | β6.3% | 4.7% | 5.6% | β | 5.0% | 3.3% | 2.7% | 9.4% | 2.2% |
| Financial health | ||||||||||
| Net debt / EBITDA | β | β0.6x | β1.0x | 1.2x | β | β | β | β | β | β |
| Debt / equity | β | 0.1x | 0.0x | 0.2x | 0.3x | 0.0x | 0.0x | 0.0x | 0.1x | 0.3x |
| Interest coverage | 511.3x | 7.3x | 38.1x | 0.6x | β21.5x | β28.9x | β43.9x | β88.8x | β44.1x | β36.9x |
| Current ratio | 4.3x | 1.4x | 3.2x | 3.0x | 2.7x | 2.4x | 2.0x | 2.0x | 1.8x | 2.5x |
| Quick ratio | 3.8x | 1.2x | 2.9x | 2.7x | 2.5x | 2.3x | 1.9x | 1.9x | 1.6x | 2.3x |
| Capital allocation | ||||||||||
| Capex / revenue | 0.7% | 0.8% | 1.1% | 1.0% | 1.6% | 2.6% | 6.7% | β | β | β |
| Stock comp / revenue | 4.2% | 3.9% | 3.6% | 3.9% | 3.9% | 5.3% | 5.6% | 5.4% | 5.9% | 4.3% |
| Payouts / FCF | 100.8% | 31.6% | 0.0% | 66.6% | 0.0% | 0.0% | β | β | β | β |
| Quality scores | ||||||||||
| Piotroski F-score | β | 4.0 | 5.0 | 3.0 | β | 5.0 | 2.0 | 3.0 | 4.0 | 5.0 |
| Altman Z'' | 8.6 | 2.3 | 7.0 | 3.5 | 1.2 | 2.7 | 1.9 | β0.1 | β0.1 | β5.9 |
| Accruals ratio | β5.6% | β8.5% | 1.5% | β5.8% | β18.3% | β3.3% | β0.5% | β13.0% | β10.9% | β42.4% |
Source: SEC EDGAR XBRL filings (CIK 0000899923). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
